Document is current
Any future updates will be listed below
-
Authors
Ramli, Fitri Fareez
Singh, Nisha
Villa, Luca M.
Waters, Shona
Harmer, Catherine J.
Cowen, Philip J.
Godlewska, Beata R. https://orcid.org/0000-0002-5973-3765
-
Funding
Funding for this research was provided by:
Medical Research Council (MR/K022202)
NIHR Oxford Health Biomedical Research Centre (NIHR Oxford Health Biomedical Research Centre)
Yayasan Khazanah (Yayasan Khazanah)
- License Information
-
More Information
Article History
Received: 17 October 2024
Accepted: 1 July 2025
First Online: 11 July 2025
Declarations
:
: The study was approved by the National Research Ethics Service Committee (NRES), South-Central Oxford (ID:20/SC/0151). The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013.
: Informed written consent was obtained from all participants before the study.
: N/A.
: PJC holds a patent on behalf of Oxford University for the use of ebselen in patients with resistant depression. CJH was supported by the NIHR Oxford Health Biomedical Research Centre; she has received consultancy fees from P1vital, Lundbeck, Servier, UCB, Zogenix, J&J, IESO outside of the current work. LMV is employed by Qynapse. BRG has received consultancy fees from Tiefenbacher Pharmaceuticals. FFR, and SW declare no conflicts of interest. NS holds a method-of-use patent (WO/2012/107735) for ebselen in the treatment of bipolar disorder.
